Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET
Company Participants
Todd Tushla - Vice President of Investor Relations
Kevin Gorman - Chief Executive Officer
Matt Abernethy - Chief Financial Officer
Eiry Roberts - Chief Medical Officer
Eric Benevich - Chief Commercial Officer
Kyle Gano - Chief Business Development and Strategy Officer
Conference Call Participants
Phil Nadeau - Cowen & Company
Leonid Timashev - RBC Capital Markets
Paul Matteis - Stifel
Tazeen Ahmad - Bank of America
Neena Bitritto-Garg - Citi
Jay Olson - Oppenheimer
Carter Gould - Barclays
Anupam Rama - JPMorgan
Brian Skorney - Baird
Chris Shibutani - Goldman Sachs
Myles Minter - William Blair
Danielle Brill - Raymond James
Laura Chico - Wedbush
Marc Goodman - SVB
David Amsellem - Piper Sandler
Yatin Suneja - Guggenheim Partners
Operator
Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Second Quarter Results [Operator Instructions]. Please note today's call may be recorded, and I will be stnading by should you need any assistance.
It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.
Todd Tushla
Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2022 earnings call. With me are Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer. During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we'll head into Q&A where we'll try to get to everyone's questions.
And now I'll turn the call over to Kevin Gorman.
Kevin Gorman
Thank you, Todd, and good afternoon. As Todd said, we're going to -- I'll keep our opening remarks short to give us enough time for your questions. INGREZZA had a very good Q2. And coupled with our outperformance in Q1, we have had an excellent first half of the year. Eric is going to take you through the quarter in a bit more detail in just a moment. Now in addition, I'm very pleased to say we continue to grow our pipeline, adding two new compounds with validated mechanisms of action in psychiatry, and Eiry will talk a bit about those two. Now as you've seen in our press release, our signal seeking essential tremor study did not yield a strong enough data set to warrant any further development of this compound in ET at this time. While disappointing, we have a rich and diversified portfolio and these resources will be rapidly redeployed.